Cautious Roche Stresses: 'It's Not Only About APHINITY'

Roche is suddenly sounding less optimistic about its Phase III APHINITY trial of Perjeta in the neoadjuvant breast cancer setting – stressing that 2017 will also bring three other key readouts for the company.